J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Alkermes (ALKS) on January 13. The company’s shares closed last Tuesday at $22.85, close to its 52-week high of $23.02.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.4% and a 57.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Alkermes is a Hold with an average price target of $22.17, which is a -2.4% downside from current levels. In a report issued on January 12, Evercore ISI also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Alkermes’ market cap is currently $3.64B and has a P/E ratio of -48.50. The company has a Price to Book ratio of 4.09.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALKS in relation to earlier this year. Earlier this month, Wendy Dixon, a Director at ALKS bought 35,000 shares for a total of $441,700.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.